{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:14:18Z","timestamp":1772817258574,"version":"3.50.1"},"publisher-location":"Cham","reference-count":131,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319048420","type":"print"},{"value":"9783319048437","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-3-319-04843-7_18","type":"book-chapter","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T13:44:45Z","timestamp":1402580685000},"page":"323-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Genetically Modified T-Cell Therapy for Osteosarcoma"],"prefix":"10.1007","author":[{"given":"Christopher","family":"DeRenzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,2]]},"reference":[{"key":"18_CR1","doi-asserted-by":"crossref","unstructured":"Ahmed N, Brawley V, Diouf O et al (2012) T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma. Cancer Res 72(8 Suppl 1):Abstract","DOI":"10.1158\/1538-7445.AM2012-3500"},{"issue":"10","key":"18_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/mt.2009.133","volume":"17","author":"N Ahmed","year":"2009","unstructured":"Ahmed N, Salsman VS, Yvon E et al (2009) Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17(10):1779\u20131787","journal-title":"Mol Ther"},{"issue":"1","key":"18_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI32103","volume":"118","author":"C Berger","year":"2008","unstructured":"Berger C, Jensen MC, Lansdorp PM et al (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118(1):294\u2013305","journal-title":"J Clin Invest"},{"issue":"5","key":"18_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1939-1676.2010.0557.x","volume":"24","author":"BJ Biller","year":"2010","unstructured":"Biller BJ, Guth A, Burton JH et al (2010) Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med 24(5):1118\u20131123","journal-title":"J Vet Intern Med"},{"issue":"12","key":"18_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1084\/jem.20040890","volume":"200","author":"CM Bollard","year":"2004","unstructured":"Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for epstein-barr virus+ Hodgkin\u2019s disease. J Exp Med 200(12):1623\u20131633","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"18_CR6","first-page":"S22","volume":"20","author":"CM Bollard","year":"2012","unstructured":"Bollard CM, Dotti G, Gottschalk S et al (2012) Administration of TGF-beta resistant tumor-specific CTL to patients with EBV-associated HL and NHL. Mol Ther 20(Suppl 1):S22","journal-title":"Mol Ther"},{"issue":"8","key":"18_CR7","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","volume":"110","author":"CM Bollard","year":"2007","unstructured":"Bollard CM, Gottschalk S, Leen AM et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110(8):2838\u20132845","journal-title":"Blood"},{"issue":"9","key":"18_CR8","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","volume":"99","author":"CM Bollard","year":"2002","unstructured":"Bollard CM, Rossig C, Calonge MJ et al (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99(9):3179\u20133187","journal-title":"Blood"},{"issue":"1 Suppl","key":"18_CR9","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.bbmt.2010.09.019","volume":"17","author":"C Bonini","year":"2011","unstructured":"Bonini C, Brenner MK, Heslop HE et al (2011) Genetic modification of T cells. Biol Blood Marrow Transplant 17(1 Suppl):S15\u2013S20","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"18_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"2","key":"18_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.coi.2010.01.020","volume":"22","author":"MK Brenner","year":"2010","unstructured":"Brenner MK, Heslop HE (2010) Adoptive T cell therapy of cancer. Curr Opin Immunol 22(2):251\u2013257","journal-title":"Curr Opin Immunol"},{"issue":"177","key":"18_CR12","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38","journal-title":"Sci Transl Med"},{"issue":"3","key":"18_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9(3):279\u2013286","journal-title":"Nat Med"},{"issue":"9","key":"18_CR14","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R et al (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106(9):3360\u20133365","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"18_CR15","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323\u20135337","journal-title":"Clin Cancer Res"},{"issue":"4","key":"18_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/153685903322328938","volume":"22","author":"NK Cheung","year":"2003","unstructured":"Cheung NK, Guo HF, Modak S et al (2003) Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybrid Hybridomics 22(4):209\u2013218","journal-title":"Hybrid Hybridomics"},{"issue":"11","key":"18_CR17","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","volume":"73","author":"D Chinnasamy","year":"2013","unstructured":"Chinnasamy D, Tran E, Yu Z et al (2013) Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res 73(11):3371\u20133380","journal-title":"Cancer Res"},{"issue":"6","key":"18_CR18","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","volume":"18","author":"D Chinnasamy","year":"2012","unstructured":"Chinnasamy D, Yu Z, Kerkar SP et al (2012) Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18(6):1672\u20131683","journal-title":"Clin Cancer Res"},{"issue":"11","key":"18_CR19","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","volume":"120","author":"D Chinnasamy","year":"2010","unstructured":"Chinnasamy D, Yu Z, Theoret MR et al (2010) Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 120(11):3953\u20133968","journal-title":"J Clin Invest"},{"issue":"2","key":"18_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/CJI.0b013e31824300c7","volume":"35","author":"J Chou","year":"2012","unstructured":"Chou J, Voong LN, Mortales CL et al (2012) Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother 35(2):131\u2013141","journal-title":"J Immunother"},{"issue":"5","key":"18_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","volume":"10","author":"F Ciceri","year":"2009","unstructured":"Ciceri F, Bonini C, Stanghellini MT et al (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10(5):489\u2013500","journal-title":"Lancet Oncol"},{"issue":"4","key":"18_CR22","first-page":"482","volume":"1","author":"P Cirri","year":"2011","unstructured":"Cirri P, Chiarugi P (2011) Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 1(4):482\u2013497","journal-title":"Am J Cancer Res"},{"issue":"8","key":"18_CR23","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1158\/0008-5472.CAN-06-3986","volume":"67","author":"CJ Cohen","year":"2007","unstructured":"Cohen CJ, Li YF, El-Gamil M et al (2007) Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 67(8):3898\u20133903","journal-title":"Cancer Res"},{"issue":"35","key":"18_CR24","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli P, Pedrazzoli P, Maccario R et al (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23(35):8942\u20138949","journal-title":"J Clin Oncol"},{"issue":"4","key":"18_CR25","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2004-03-1208","volume":"105","author":"LJ Cooper","year":"2005","unstructured":"Cooper LJ, Al Kadhimi Z, Serrano LM et al (2005) Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105(4):1622\u20131631","journal-title":"Blood"},{"issue":"8","key":"18_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock JA, Lu A, Bear A et al (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33(8):780\u2013788","journal-title":"J Immunother"},{"issue":"22","key":"18_CR27","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-11-1873","volume":"17","author":"CR Cruz","year":"2011","unstructured":"Cruz CR, Gerdemann U, Leen AM et al (2011) Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res 17(22):7058\u20137066","journal-title":"Clin Cancer Res"},{"issue":"18","key":"18_CR28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673\u20131683","journal-title":"N Engl J Med"},{"issue":"9","key":"18_CR29","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.4161\/onci.21940","volume":"1","author":"M Donia","year":"2012","unstructured":"Donia M, Fagone P, Nicoletti F et al (2012) BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 1(9):1476\u20131483","journal-title":"Oncoimmunology"},{"issue":"12","key":"18_CR30","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","volume":"105","author":"G Dotti","year":"2005","unstructured":"Dotti G, Savoldo B, Pule M et al (2005) Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105(12):4677\u20134684","journal-title":"Blood"},{"issue":"32","key":"18_CR31","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233\u20135239","journal-title":"J Clin Oncol"},{"issue":"2","key":"18_CR32","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G et al (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90(2):720\u2013724","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"18_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","volume":"31","author":"AE Foster","year":"2008","unstructured":"Foster AE, Dotti G, Lu A et al (2008) Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 31(5):500\u2013505","journal-title":"J Immunother"},{"issue":"3","key":"18_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<284::AID-PATH94>3.0.CO;2-Z","volume":"185","author":"A Franchi","year":"1998","unstructured":"Franchi A, Arganini L, Baroni G et al (1998) Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas. J Pathol 185(3):284\u2013289","journal-title":"J Pathol"},{"issue":"4","key":"18_CR35","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.4049\/jimmunol.180.4.2089","volume":"180","author":"M Fujita","year":"2008","unstructured":"Fujita M, Zhu X, Sasaki K et al (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180(4):2089\u20132098","journal-title":"J Immunol"},{"key":"18_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","volume":"213","author":"TF Gajewski","year":"2006","unstructured":"Gajewski TF, Meng Y, Blank C et al (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131\u2013145","journal-title":"Immunol Rev"},{"issue":"10","key":"18_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00262-010-0882-5","volume":"59","author":"SL Goff","year":"2010","unstructured":"Goff SL, Johnson LA, Black MA et al (2010) Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol Immunother 59(10):1551\u20131560","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"18_CR38","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.1999.17.9.2781","volume":"17","author":"R Gorlick","year":"1999","unstructured":"Gorlick R, Huvos AG, Heller G et al (1999) Expression of HER2\/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17(9):2781\u20132788","journal-title":"J Clin Oncol"},{"key":"18_CR39","doi-asserted-by":"crossref","unstructured":"Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518","DOI":"10.1056\/NEJMoa1215134"},{"issue":"3","key":"18_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309\u2013322","journal-title":"Cancer Cell"},{"issue":"19","key":"18_CR41","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","volume":"70","author":"A Herrmann","year":"2010","unstructured":"Herrmann A, Kortylewski M, Kujawski M et al (2010) Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 70(19):7455\u20137464","journal-title":"Cancer Res"},{"issue":"5","key":"18_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA et al (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5):925\u2013935","journal-title":"Blood"},{"issue":"8","key":"18_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"6","key":"18_CR44","first-page":"1116","volume":"58","author":"A Hombach","year":"1998","unstructured":"Hombach A, Heuser C, Sircar R et al (1998) An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin\u2019s lymphoma cells in the presence of soluble CD30. Cancer Res 58(6):1116\u20131119","journal-title":"Cancer Res"},{"issue":"6","key":"18_CR45","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos V, Savoldo B, Quintarelli C et al (2010) Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia 24(6):1160\u20131170","journal-title":"Leukemia"},{"issue":"1","key":"18_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","volume":"72","author":"G Huang","year":"2012","unstructured":"Huang G, Yu L, Cooper LJ et al (2012) Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 72(1):271\u2013281","journal-title":"Cancer Res"},{"issue":"4","key":"18_CR47","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/10430340050015798","volume":"11","author":"M Introna","year":"2000","unstructured":"Introna M, Barbui AM, Bambacioni F et al (2000) Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 11(4):611\u2013620","journal-title":"Hum Gene Ther"},{"issue":"2","key":"18_CR48","first-page":"461","volume":"30","author":"H Ishikura","year":"2007","unstructured":"Ishikura H, Ikeda H, Abe H et al (2007) Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system. Int J Oncol 30(2):461\u2013467","journal-title":"Int J Oncol"},{"issue":"1","key":"18_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ijc.22118","volume":"120","author":"JF Jacobs","year":"2007","unstructured":"Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA et al (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120(1):67\u201374","journal-title":"Int J Cancer"},{"issue":"20","key":"18_CR50","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CM et al (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636\u20135646","journal-title":"Clin Cancer Res"},{"issue":"3","key":"18_CR51","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3):535\u2013546","journal-title":"Blood"},{"issue":"7","key":"18_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nbt.2305","volume":"30","author":"C June","year":"2012","unstructured":"June C, Rosenberg SA, Sadelain M et al (2012) T-cell therapy at the threshold. Nat Biotechnol 30(7):611\u2013614","journal-title":"Nat Biotechnol"},{"key":"18_CR53","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","volume":"21","author":"S Kakarla","year":"2013","unstructured":"Kakarla S, Chow KK, Mata M et al (2013) Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 21:1611\u20131620","journal-title":"Mol Ther"},{"issue":"95","key":"18_CR54","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73","journal-title":"Sci Transl Med"},{"key":"18_CR55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"18_CR56","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/mt.2013.58","volume":"21","author":"SP Kerkar","year":"2013","unstructured":"Kerkar SP, Leonardi AJ, van Panhuys N (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21(7):1369\u20131377","journal-title":"Mol Ther"},{"issue":"16","key":"18_CR57","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1089\/10430340260355374","volume":"13","author":"MH Kershaw","year":"2002","unstructured":"Kershaw MH, Wang G, Westwood JA et al (2002) Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 13(16):1971\u20131980","journal-title":"Hum Gene Ther"},{"issue":"20 Pt 1","key":"18_CR58","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1):6106\u20136115","journal-title":"Clin Cancer Res"},{"issue":"1","key":"18_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M et al (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31(1):71\u201375","journal-title":"Nat Biotechnol"},{"issue":"12","key":"18_CR60","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12):2709\u20132720","journal-title":"Blood"},{"issue":"12","key":"18_CR61","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371\u20134383","journal-title":"Blood"},{"issue":"13","key":"18_CR62","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers CH, Sleijfer S, Vulto AG et al (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24(13):e20\u2013e22","journal-title":"J Clin Oncol"},{"key":"18_CR63","doi-asserted-by":"crossref","unstructured":"Lanitis E, Poussin M, Klattenhof A et al (2013) Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res (OnLine First April 7, 2013)","DOI":"10.1158\/2326-6066.CIR-13-0008"},{"issue":"26","key":"18_CR64","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen AM, Bollard CM, Mendizabal AM et al (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121(26):5113\u20135123","journal-title":"Blood"},{"issue":"10","key":"18_CR65","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nm1475","volume":"12","author":"AM Leen","year":"2006","unstructured":"Leen AM, Myers GD, Sili U et al (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12(10):1160\u20131166","journal-title":"Nat Med"},{"key":"18_CR66","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","volume":"25","author":"AM Leen","year":"2007","unstructured":"Leen AM, Rooney CM, Foster AE (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25:243\u2013265","journal-title":"Annu Rev Immunol"},{"issue":"S1","key":"18_CR67","first-page":"S194","volume":"19","author":"A Leen","year":"2011","unstructured":"Leen A, Katari U, Keiman J et al (2011) Improved expansion and anti-tumor activity of tumor-specific CTLs using a transgenic chimeric cytokine receptor. Mol Ther 19(S1):S194","journal-title":"Mol Ther"},{"issue":"S1","key":"18_CR68","first-page":"S114","volume":"21","author":"BL Levine","year":"2013","unstructured":"Levine BL, Rapoport AP, Stadtmauer EA et al (2013) Safety and correlates of clinical response in an early phase clinical trial in multiple myeloma patients post auto-SCT and adoptive immunotherapy with engineered T cells expressing an HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1. Mol Ther 21(S1):S114","journal-title":"Mol Ther"},{"issue":"2","key":"18_CR69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","volume":"19","author":"C Liu","year":"2013","unstructured":"Liu C, Peng W, Xu C et al (2013) BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 19(2):393\u2013403","journal-title":"Clin Cancer Res"},{"issue":"18","key":"18_CR70","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1158\/0008-5472.CAN-04-1621","volume":"64","author":"Y Lou","year":"2004","unstructured":"Lou Y, Wang G, Lizee G et al (2004) Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64(18):6783\u20136790","journal-title":"Cancer Res"},{"issue":"23","key":"18_CR71","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23):6050\u20136056","journal-title":"Blood"},{"issue":"9","key":"18_CR72","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","volume":"33","author":"CU Louis","year":"2010","unstructured":"Louis CU, Straathof K, Bollard CM et al (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33(9):983\u2013990","journal-title":"J Immunother"},{"key":"18_CR73","first-page":"278093","volume":"2012","author":"J Maher","year":"2012","unstructured":"Maher J (2012) Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012:278093","journal-title":"ISRN Oncol"},{"issue":"suppl","key":"18_CR74","first-page":"S24","volume":"21","author":"MV Maus","year":"2013","unstructured":"Maus MV, Linette GP, Stadtmauer EA et al (2013) Cardiovascular toxicity and Titin cross-reactivity of affinity-enhanced TCR-engineered T cells against HLA-A1 restricted MAGE-A3 antigen. Mol Ther 21(suppl):S24","journal-title":"Mol Ther"},{"issue":"10","key":"18_CR75","first-page":"4048","volume":"61","author":"S Modak","year":"2001","unstructured":"Modak S, Kramer K, Gultekin SH et al (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61(10):4048\u20134054","journal-title":"Cancer Res"},{"issue":"2","key":"18_CR76","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133\u2013151","journal-title":"J Immunother"},{"issue":"5796","key":"18_CR77","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126\u2013129","journal-title":"Science"},{"issue":"4","key":"18_CR78","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843\u2013851","journal-title":"Mol Ther"},{"key":"18_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/00003086-200101000-00010","volume":"382","author":"CD Morris","year":"2001","unstructured":"Morris CD, Gorlick R, Huvos G et al (2001) Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 382:59\u201365","journal-title":"Clin Orthop Relat Res"},{"issue":"S1","key":"18_CR80","first-page":"S5","volume":"22","author":"D Myers","year":"2013","unstructured":"Myers D, Jun J, Rooney C et al (2013) Administration of GD2 chimeric antigen receptor modified, tri-virus specific cytotoxic T lymphocytes after HLA mismatched allogeneic stem cell transplantation for relapsed, refractory neuroblastoma. Mol Ther 22(S1):S5\u2013S6","journal-title":"Mol Ther"},{"issue":"10","key":"18_CR81","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1073\/pnas.092562399","volume":"99","author":"TM Niederman","year":"2002","unstructured":"Niederman TM, Ghogawala Z, Carter BS et al (2002) Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A 99(10):7009\u20137014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"18_CR82","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1158\/0008-5472.CAN-09-1450","volume":"69","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Mineno J, Ikeda H et al (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69(23):9003\u20139011","journal-title":"Cancer Res"},{"issue":"5","key":"18_CR83","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1158\/1078-0432.CCR-12-3792","volume":"19","author":"RJ Orentas","year":"2013","unstructured":"Orentas RJ (2013) Reading the tea leaves of tumor-mediated immunosuppression. Clin Cancer Res 19(5):955\u2013957","journal-title":"Clin Cancer Res"},{"key":"18_CR84","first-page":"3","volume":"2","author":"RJ Orentas","year":"2012","unstructured":"Orentas RJ, Lee DW, Mackall C (2012) Immunotherapy targets in pediatric cancer. Front Oncol 2:3","journal-title":"Front Oncol"},{"issue":"4","key":"18_CR85","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1084\/jem.20030590","volume":"198","author":"WW Overwijk","year":"2003","unstructured":"Overwijk WW, Theoret MR, Finkelstein SE et al (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198(4):569\u2013580","journal-title":"J Exp Med"},{"issue":"4","key":"18_CR86","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","volume":"15","author":"JR Park","year":"2007","unstructured":"Park JR, Digiusto DL, Slovak M et al (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15(4):825\u2013833","journal-title":"Mol Ther"},{"issue":"3","key":"18_CR87","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Yang JC, Langan RC et al (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620\u2013626","journal-title":"Mol Ther"},{"issue":"1","key":"18_CR88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2249.2009.03912.x","volume":"157","author":"KS Peggs","year":"2009","unstructured":"Peggs KS, Quezada SA, Allison JP (2009) Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 157(1):9\u201319","journal-title":"Clin Exp Immunol"},{"issue":"18","key":"18_CR89","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG et al (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18):4133\u20134141","journal-title":"Blood"},{"issue":"1","key":"18_CR90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-12-2143","volume":"19","author":"SK Perna","year":"2013","unstructured":"Perna SK, De AB, Pagliara D et al (2013) Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res 19(1):106\u2013117","journal-title":"Clin Cancer Res"},{"issue":"1","key":"18_CR91","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tig.2008.10.012","volume":"25","author":"K Polyak","year":"2009","unstructured":"Polyak K, Haviv I, Campbell IG (2009) Co-evolution of tumor cells and their microenvironment. Trends Genet 25(1):30\u201338","journal-title":"Trends Genet"},{"issue":"8","key":"18_CR92","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725\u2013733","journal-title":"N Engl J Med"},{"issue":"11","key":"18_CR93","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14(11):1264\u20131270","journal-title":"Nat Med"},{"issue":"5","key":"18_CR94","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pule","year":"2005","unstructured":"Pule MA, Straathof KC, Dotti G et al (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12(5):933\u2013941","journal-title":"Mol Ther"},{"issue":"8","key":"18_CR95","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1182\/blood-2007-02-072843","volume":"110","author":"C Quintarelli","year":"2007","unstructured":"Quintarelli C, Vera JF, Savoldo B et al (2007) Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110(8):2793\u20132802","journal-title":"Blood"},{"key":"18_CR96","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","volume":"25","author":"GA Rabinovich","year":"2007","unstructured":"Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267\u2013296","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"18_CR97","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/cgt.2011.83","volume":"19","author":"N Rainusso","year":"2012","unstructured":"Rainusso N, Brawley VS, Ghazi A et al (2012) Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 19(3):212\u2013217","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"18_CR98","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269\u2013281","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"18_CR99","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29(7):917\u2013924","journal-title":"J Clin Oncol"},{"issue":"6","key":"18_CR100","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.20122344","volume":"210","author":"EW Roberts","year":"2013","unstructured":"Roberts EW, Deonarine A, Jones JO et al (2013) Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 210(6):1137\u20131151","journal-title":"J Exp Med"},{"issue":"4","key":"18_CR101","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC et al (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299\u2013308","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"18_CR102","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ijc.1457","volume":"94","author":"C Rossig","year":"2001","unstructured":"Rossig C, Bollard CM, Nuchtern JG et al (2001) Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 94(2):228\u2013236","journal-title":"Int J Cancer"},{"issue":"22","key":"18_CR103","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1158\/1078-0432.CCR-08-0499","volume":"14","author":"C Rouleau","year":"2008","unstructured":"Rouleau C, Curiel M, Weber W et al (2008) Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res 14(22):7223\u20137236","journal-title":"Clin Cancer Res"},{"issue":"4","key":"18_CR104","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388\u2013398","journal-title":"Cancer Discov"},{"issue":"5","key":"18_CR105","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822\u20131826","journal-title":"J Clin Invest"},{"issue":"7","key":"18_CR106","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","volume":"110","author":"B Savoldo","year":"2007","unstructured":"Savoldo B, Rooney CM, Di Stasi A et al (2007) Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110(7):2620\u20132630","journal-title":"Blood"},{"issue":"4","key":"18_CR107","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/gt.2012.48","volume":"20","author":"PC Schuberth","year":"2013","unstructured":"Schuberth PC, Jakka G, Jensen SM et al (2013) Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther 20(4):386\u2013395","journal-title":"Gene Ther"},{"issue":"1","key":"18_CR108","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/mt.2010.223","volume":"19","author":"XT Song","year":"2010","unstructured":"Song XT, Turnis M, Zhou X et al (2010) A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther 19(1):211\u2013217","journal-title":"Mol Ther"},{"issue":"12","key":"18_CR109","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan MT, Ponomarev V, Brentjens RJ et al (2007) T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13(12):1440\u20131449","journal-title":"Nat Med"},{"key":"18_CR110","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Bollard CM, Popat U et al (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr Virus-specific T lymphocytes. Blood 105:1898\u20131904","journal-title":"Blood"},{"issue":"11","key":"18_CR111","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pule MA, Yotnda P et al (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105(11):4247\u20134254","journal-title":"Blood"},{"issue":"11","key":"18_CR112","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/mt.2010.185","volume":"18","author":"J Sun","year":"2010","unstructured":"Sun J, Dotti G, Huye LE et al (2010) T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 18(11):2006\u20132017","journal-title":"Mol Ther"},{"issue":"6","key":"18_CR113","first-page":"682","volume":"79","author":"CM Sutherland","year":"1976","unstructured":"Sutherland CM, Krementz ET, Hornung MO et al (1976) Transfer of in vitro cytotoxicity against osteogenic sarcoma cells. Surgery 79(6):682\u2013685","journal-title":"Surgery"},{"issue":"1","key":"18_CR114","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2011-07-366419","volume":"119","author":"S Terakura","year":"2012","unstructured":"Terakura S, Yamamoto TN, Gardner RA et al (2012) Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119(1):72\u201382","journal-title":"Blood"},{"issue":"5","key":"18_CR115","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN et al (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541\u2013547","journal-title":"Immunity"},{"issue":"24","key":"18_CR116","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu PQ et al (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119(24):5697\u20135705","journal-title":"Blood"},{"issue":"6","key":"18_CR117","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z et al (2013) Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 210(6):1125\u20131135","journal-title":"J Exp Med"},{"issue":"2","key":"18_CR118","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1349-7006.2008.00695.x","volume":"99","author":"T Tsukahara","year":"2008","unstructured":"Tsukahara T, Kawaguchi S, Torigoe T et al (2008) Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci 99(2):368\u2013375","journal-title":"Cancer Sci"},{"issue":"8","key":"18_CR119","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10585-009-9290-7","volume":"26","author":"H Urakawa","year":"2009","unstructured":"Urakawa H, Nishida Y, Nakashima H et al (2009) Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 26(8):1005\u20131012","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"18_CR120","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/jgm.2637","volume":"14","author":"BJ Uttenthal","year":"2012","unstructured":"Uttenthal BJ, Chua I, Morris EC et al (2012) Challenges in T cell receptor gene therapy. J Gene Med 14(6):386\u2013399","journal-title":"J Gene Med"},{"key":"18_CR121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1034\/j.1600-065X.2002.18806.x","volume":"188","author":"P van Der Bruggen","year":"2002","unstructured":"van Der Bruggen P, Zhang Y, Chaux P et al (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51\u201364","journal-title":"Immunol Rev"},{"issue":"4","key":"18_CR122","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237\u2013251","journal-title":"Nat Rev Cancer"},{"issue":"S1","key":"18_CR123","first-page":"S153","volume":"22","author":"N Watanabe","year":"2013","unstructured":"Watanabe N, Anurathapan U, Brenner M et al (2013) Transgenic expression of a novel immunosuppressive signal converter on T cells. Mol Ther 22(S1):S153","journal-title":"Mol Ther"},{"issue":"5238","key":"18_CR124","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, Penninger JM, Timms E et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985\u2013988","journal-title":"Science"},{"issue":"33","key":"18_CR125","doi-asserted-by":"publisher","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","volume":"285","author":"S Wilkie","year":"2010","unstructured":"Wilkie S, Burbridge SE, Chiapero-Stanke L et al (2010) Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 285(33):25538\u201325544","journal-title":"J Biol Chem"},{"issue":"5","key":"18_CR126","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie S, van Schalkwyk MC, Hobbs S et al (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32(5):1059\u20131070","journal-title":"J Clin Immunol"},{"issue":"21","key":"18_CR127","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/sj.gt.3301570","volume":"8","author":"RA Willemsen","year":"2001","unstructured":"Willemsen RA, Debets R, Hart E et al (2001) A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 8(21):1601\u20131608","journal-title":"Gene Ther"},{"issue":"6","key":"18_CR128","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","volume":"31","author":"L Yang","year":"2010","unstructured":"Yang L, Pang Y, Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31(6):220\u2013227","journal-title":"Trends Immunol"},{"issue":"6","key":"18_CR129","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.1998.16.6.2169","volume":"16","author":"AL Yu","year":"1998","unstructured":"Yu AL, Uttenreuther-Fischer MM, Huang CS et al (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16(6):2169\u20132180","journal-title":"J Clin Oncol"},{"issue":"3","key":"18_CR130","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jso.23368","volume":"108","author":"D Yuan","year":"2013","unstructured":"Yuan D, Liu B, Liu K et al (2013) Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma. J Surg Oncol 108(3):157\u2013162","journal-title":"J Surg Oncol"},{"issue":"4","key":"18_CR131","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang L, Kerkar SP, Yu Z et al (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19(4):751\u2013759","journal-title":"Mol Ther"}],"container-title":["Advances in Experimental Medicine and Biology","Current Advances in Osteosarcoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-04843-7_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T18:05:47Z","timestamp":1676657147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-04843-7_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9783319048420","9783319048437"],"references-count":131,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-04843-7_18","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"2 May 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}